Shorter radiation with a focused boost for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have high-risk or locally advanced prostate cancer that has not spread to distant organs.
- You have not had prior treatment for your prostate cancer (like surgery, radiation, or chemotherapy).
- You are willing to receive hormone therapy for 12 to 36 months.
- You can have an MRI to find a visible tumor target for the radiation boost.
- You agree to use condoms or other effective contraception during radiation and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.